TapImmune, Inc. announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin(R)-based therapy and are at risk of disease recurrence.